| pubmed-article:6599676 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6599676 | lifeskim:mentions | umls-concept:C0020538 | lld:lifeskim |
| pubmed-article:6599676 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:6599676 | lifeskim:mentions | umls-concept:C1801960 | lld:lifeskim |
| pubmed-article:6599676 | lifeskim:mentions | umls-concept:C0011710 | lld:lifeskim |
| pubmed-article:6599676 | lifeskim:mentions | umls-concept:C0037494 | lld:lifeskim |
| pubmed-article:6599676 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:6599676 | lifeskim:mentions | umls-concept:C0813203 | lld:lifeskim |
| pubmed-article:6599676 | lifeskim:mentions | umls-concept:C0332208 | lld:lifeskim |
| pubmed-article:6599676 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:6599676 | lifeskim:mentions | umls-concept:C0000975 | lld:lifeskim |
| pubmed-article:6599676 | lifeskim:mentions | umls-concept:C1880177 | lld:lifeskim |
| pubmed-article:6599676 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:6599676 | pubmed:dateCreated | 1986-6-25 | lld:pubmed |
| pubmed-article:6599676 | pubmed:abstractText | The role of arginine-vasopressin (AVP) in the pathogenesis of deoxycorticosterone acetate (DOCA) salt hypertension in rats was studied with AVP receptor antagonists for its tubular (V2) and/or vascular (V1) actions. When chronic (six weeks) infusion of the antagonists was started concomitantly with DOCA-salt treatment the development of hypertension was attenuated by the V1-antagonist and prevented by the V1V2-antagonist. However, the V1V2-antagonist induced severe and persistent hypernatraemia in all rats. When chronic (two weeks) infusion of the antagonists was started in rats with established hypertension after five weeks of DOCA-salt treatment blood pressure was not influenced by the V1-antagonist. The rats which received the V1V2-antagonist died from hypernatraemia within four days. These results suggest that in DOCA-salt treated rats AVP is essential for the prevention of severe and life-threatening hypernatraemia. AVP appears to contribute significantly to the development of this form of hypertension through both its vascular and tubular effects. | lld:pubmed |
| pubmed-article:6599676 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6599676 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6599676 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6599676 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6599676 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6599676 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6599676 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6599676 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6599676 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:6599676 | pubmed:issn | 0952-1178 | lld:pubmed |
| pubmed-article:6599676 | pubmed:author | pubmed-author:WoodJ MJM | lld:pubmed |
| pubmed-article:6599676 | pubmed:author | pubmed-author:HofbauerK GKG | lld:pubmed |
| pubmed-article:6599676 | pubmed:author | pubmed-author:KraetzJJ | lld:pubmed |
| pubmed-article:6599676 | pubmed:author | pubmed-author:MayS TST | lld:pubmed |
| pubmed-article:6599676 | pubmed:author | pubmed-author:BaumH PHP | lld:pubmed |
| pubmed-article:6599676 | pubmed:author | pubmed-author:OppermanJ RJR | lld:pubmed |
| pubmed-article:6599676 | pubmed:author | pubmed-author:HänniHH | lld:pubmed |
| pubmed-article:6599676 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6599676 | pubmed:volume | 2 | lld:pubmed |
| pubmed-article:6599676 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6599676 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6599676 | pubmed:pagination | S333-5 | lld:pubmed |
| pubmed-article:6599676 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:6599676 | pubmed:meshHeading | pubmed-meshheading:6599676-... | lld:pubmed |
| pubmed-article:6599676 | pubmed:meshHeading | pubmed-meshheading:6599676-... | lld:pubmed |
| pubmed-article:6599676 | pubmed:meshHeading | pubmed-meshheading:6599676-... | lld:pubmed |
| pubmed-article:6599676 | pubmed:meshHeading | pubmed-meshheading:6599676-... | lld:pubmed |
| pubmed-article:6599676 | pubmed:meshHeading | pubmed-meshheading:6599676-... | lld:pubmed |
| pubmed-article:6599676 | pubmed:meshHeading | pubmed-meshheading:6599676-... | lld:pubmed |
| pubmed-article:6599676 | pubmed:meshHeading | pubmed-meshheading:6599676-... | lld:pubmed |
| pubmed-article:6599676 | pubmed:meshHeading | pubmed-meshheading:6599676-... | lld:pubmed |
| pubmed-article:6599676 | pubmed:meshHeading | pubmed-meshheading:6599676-... | lld:pubmed |
| pubmed-article:6599676 | pubmed:meshHeading | pubmed-meshheading:6599676-... | lld:pubmed |
| pubmed-article:6599676 | pubmed:meshHeading | pubmed-meshheading:6599676-... | lld:pubmed |
| pubmed-article:6599676 | pubmed:meshHeading | pubmed-meshheading:6599676-... | lld:pubmed |
| pubmed-article:6599676 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6599676 | pubmed:articleTitle | Contribution of vascular and tubular effects of arginine-vasopressin to the development of deoxycorticosterone acetate (DOCA)-salt hypertension in rats. | lld:pubmed |
| pubmed-article:6599676 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6599676 | pubmed:publicationType | Comparative Study | lld:pubmed |
